Outcomes of selective laser trabeculoplasty in corticosteroid-induced ocular hypertension and glaucoma

Eur J Ophthalmol. 2022 May;32(3):1525-1529. doi: 10.1177/11206721211023310. Epub 2021 Jun 6.

Abstract

Purpose: To report the outcomes of selective laser trabeculoplasty (SLT) in lowering intraocular pressure (IOP) in patients with steroid-induced ocular hypertension and glaucoma.

Methods: A retrospective chart review of patients who underwent SLT for steroid-induced ocular hypertension or glaucoma between January 2014 and October 2018. Success of SLT was defined as ⩾20% IOP reduction from baseline without further medical or surgical intervention and/or a reduction in the number of glaucoma medications by ⩾1 from baseline while maintaining the target IOP. Main outcome measures were change in IOP from baseline and reduction in the number of medications post-laser.

Results: A total of 25 eyes of 17 patients were included in the study. The mean duration of follow-up was 18.8 ± 4.5 months. IOP decreased from 23.7 ± 6.7 mmHg pre-laser to 14.4 ± 3.2 mmHg post-laser, at the last follow-up visit (p < 0.001). The mean number of medications was 1.8 ± 1.6 medications pre-laser and 1.4 ± 1.3 medications post-laser (p = 0.262). The overall success rate at 12 months was 72%. No visually significant complications were encountered during the whole duration of follow-up.

Conclusion: SLT is a safe and effective procedure that can result in well-controlled IOP in patients with steroid-induced ocular hypertension and glaucoma.

Keywords: Selective laser trabeculoplasty; corticosteroids; glaucoma.

MeSH terms

  • Adrenal Cortex Hormones
  • Glaucoma* / chemically induced
  • Glaucoma* / surgery
  • Humans
  • Intraocular Pressure
  • Laser Therapy* / methods
  • Ocular Hypertension* / chemically induced
  • Retrospective Studies
  • Trabeculectomy* / methods
  • Treatment Outcome

Substances

  • Adrenal Cortex Hormones